PhaseII study of S-1/CDDP therapy for Gastric Cancer that Recurs After Adjuvant Chemotherapy with S-1 - PhaseII study of S-1/CDDP therapy for Gastric Cancer that Recurs After Adjuvant Chemotherapy with S-1(KSCC1001)

Kyushu Study group of Clinical Cancer0 个研究点目标入组 44 人开始时间: 2010年9月30日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Active other malignancies. 2. Prior S-1 plus other anti-cancer drugs combination chemotherapy. 3. Adjuvant chemotherapy other than S-1 mono therapy. 4. Requiring flucytosine, phenytoin, Warfarin Potassium. 5. History of the severe(grade3 or 4) hypersensitivity 6. Co-mobility, such as interstitial lung disease, lung fibrosis, intestinal paralysis, ileus, uncontrolled diabetes, uncontrolled hypertension, heart failure, serious arrhythmia, myocardial infarction, unstable angina, hepatic failure, liver cirrhosis, requiring anticoagulation therapy, requiring steroid drug, and other severe complication. 7. Active infection 8. Infection with hepatitis B or C virus 9. Watery stools or diarrhea 10. Pregnant or lactating woman 11. No birth-control 12. Mental disorder, central nerve disorder. 13. Infection with HIV virus. 14. Not appropriate for the study at the physician's assessment

发起方

Kyushu Study group of Clinical Cancer